• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
General scientific guidance for stakeholders on health claim applications (Revision 1).利益相关者关于健康声称申请的一般科学指南(修订版1)。
EFSA J. 2021 Mar 26;19(3):e06553. doi: 10.2903/j.efsa.2021.6553. eCollection 2021 Mar.
2
Scientific and technical guidance for the preparation and presentation of a health claim application (Revision 3).健康声明申请编制与提交的科学和技术指南(第3版)
EFSA J. 2021 Mar 26;19(3):e06554. doi: 10.2903/j.efsa.2021.6554. eCollection 2021 Mar.
3
Guidance on the preparation and presentation of applications for exemption from mandatory labelling of food allergens and/or products thereof pursuant to Article 21 (2) of Regulation (EU) No 1169/2011.关于根据欧盟第1169/2011号法规第21(2)条申请豁免食品过敏原和/或其产品强制标签的准备和提交指南。
EFSA J. 2021 Mar 26;19(3):e06543. doi: 10.2903/j.efsa.2021.6543. eCollection 2021 Mar.
4
Scientific and technical guidance for the preparation and presentation of a health claim application (Revision 2).健康声明申请编制与提交的科学和技术指南(修订版2)
EFSA J. 2017 Jan 31;15(1):e04680. doi: 10.2903/j.efsa.2017.4680. eCollection 2017 Jan.
5
Scientific and technical guidance on foods for special medical purposes in the context of Article 3 of Regulation (EU) No 609/2013.关于欧盟第609/2013号法规第3条所涵盖的特殊医学用途食品的科学和技术指南。
EFSA J. 2021 Mar 26;19(3):e06544. doi: 10.2903/j.efsa.2021.6544. eCollection 2021 Mar.
6
Scientific and technical guidance for the preparation and presentation of a dossier for evaluation of an infant and/or follow-on formula manufactured from protein hydrolysates (Revision 1).关于制备和提交用于评估由蛋白质水解物制成的婴儿配方奶粉和/或后续配方奶粉的档案的科学和技术指南(修订版1)
EFSA J. 2021 Mar 26;19(3):e06556. doi: 10.2903/j.efsa.2021.6556. eCollection 2021 Mar.
7
Guidance on the scientific requirements for health claims related to muscle function and physical performance: (Revision 1).与肌肉功能和身体表现相关的健康声称的科学要求指南:(修订版1)
EFSA J. 2018 Oct 30;16(10):e05434. doi: 10.2903/j.efsa.2018.5434. eCollection 2018 Oct.
8
Guidance for the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health: (Revision 1).抗氧化剂、氧化损伤与心血管健康相关健康声称的科学要求指南:(修订版1)
EFSA J. 2018 Jan 19;16(1):e05136. doi: 10.2903/j.efsa.2018.5136. eCollection 2018 Jan.
9
Guidance on the preparation and submission of the notification and application for authorisation of traditional foods from third countries in the context of Regulation (EU) 2015/2283 (Revision 1).关于在(欧盟)2015/2283号法规(修订版1)框架下准备和提交来自第三国传统食品的通报及授权申请的指南。
EFSA J. 2021 Mar 26;19(3):e06557. doi: 10.2903/j.efsa.2021.6557. eCollection 2021 Mar.
10
Scientific substantiation of health claims in the EU.欧盟健康声称的科学依据。
Proc Nutr Soc. 2012 Feb;71(1):120-6. doi: 10.1017/S0029665111003168. Epub 2011 Sep 20.

引用本文的文献

1
Phenolic compounds naturally present in olive oil and lowering of blood LDL-cholesterol and systolic blood pressure, therefore reducing the risk of coronary heart disease: Evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006.橄榄油中天然存在的酚类化合物与降低血液低密度脂蛋白胆固醇及收缩压,从而降低冠心病风险:依据欧盟第1924/2006号法规第14条对一项健康声明的评估
EFSA J. 2025 May 23;23(5):e9470. doi: 10.2903/j.efsa.2025.9470. eCollection 2025 May.
2
Olive oil polyphenols and the maintenance of normal HDL-cholesterol concentrations: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.橄榄油多酚与正常高密度脂蛋白胆固醇浓度的维持:依据欧盟第1924/2006号法规第13(5)条对一项健康声明的评估
EFSA J. 2025 May 2;23(5):e9372. doi: 10.2903/j.efsa.2025.9372. eCollection 2025 May.
3
Pacran®, a powder obtained from cranberries, and defence against bacterial pathogens in the lower urinary tract: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.Pacran®,一种从蔓越莓中提取的粉末,以及其对下尿路细菌病原体的防御作用:根据欧盟第1924/2006号法规第13(5)条对一项健康声明的评估
EFSA J. 2025 Apr 2;23(4):e9319. doi: 10.2903/j.efsa.2025.9319. eCollection 2025 Apr.
4
Creatine and improvement in cognitive function: Evaluation of a health claim pursuant to article 13(5) of regulation (EC) No 1924/2006.肌酸与认知功能改善:依据欧盟第1924/2006号法规第13(5)条对一项健康声明的评估
EFSA J. 2024 Nov 19;22(11):e9100. doi: 10.2903/j.efsa.2024.9100. eCollection 2024 Nov.
5
Health benefits and risks of fermented foods-the PIMENTO initiative.发酵食品的健康益处与风险——皮门托计划
Front Nutr. 2024 Sep 3;11:1458536. doi: 10.3389/fnut.2024.1458536. eCollection 2024.
6
EFSA statement on the requirements for whole genome sequence analysis of microorganisms intentionally used in the food chain.欧洲食品安全局关于食物链中有意使用的微生物全基因组序列分析要求的声明。
EFSA J. 2024 Aug 12;22(8):e8912. doi: 10.2903/j.efsa.2024.8912. eCollection 2024 Aug.
7
'Citicoline' and support of the memory function: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.“胞磷胆碱”与记忆功能支持:依据欧盟第1924/2006号法规第13(5)条对一项健康声明的评估
EFSA J. 2024 Jul 4;22(7):e8861. doi: 10.2903/j.efsa.2024.8861. eCollection 2024 Jul.
8
Joselito® and lowering of LDL-cholesterol concentration, blood pressure, and reduction of coronary heart disease risk: Evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006.乔塞利托®与低密度脂蛋白胆固醇浓度降低、血压降低以及冠心病风险降低:依据欧盟第1924/2006号法规第14条对一项健康声明的评估
EFSA J. 2024 Jul 4;22(7):e8862. doi: 10.2903/j.efsa.2024.8862. eCollection 2024 Jul.
9
Dietary composition of adult eosinophilic esophagitis patients is related to disease severity.成人嗜酸性粒细胞性食管炎患者的饮食组成与疾病严重程度有关。
Immun Inflamm Dis. 2024 Mar;12(3):e1206. doi: 10.1002/iid3.1206.
10
Microbiota analysis for risk assessment of xenobiotic exposure and the impact on dysbiosis: identifying potential next-generation probiotics.用于评估外源性物质暴露风险及对生态失调影响的微生物群分析:识别潜在的下一代益生菌。
EFSA J. 2023 Nov 30;21(Suppl 1):e211010. doi: 10.2903/j.efsa.2023.e211010. eCollection 2023 Nov.

本文引用的文献

1
Scientific and technical guidance for the preparation and presentation of a health claim application (Revision 3).健康声明申请编制与提交的科学和技术指南(第3版)
EFSA J. 2021 Mar 26;19(3):e06554. doi: 10.2903/j.efsa.2021.6554. eCollection 2021 Mar.
2
Towards a taxonomic coherence between average nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of prokaryotes.为了在原核生物的种系划分中实现平均核苷酸同一性和 16S rRNA 基因序列相似性之间的分类学一致性。
Int J Syst Evol Microbiol. 2014 Feb;64(Pt 2):346-351. doi: 10.1099/ijs.0.059774-0.
3
Integrating genomics into the taxonomy and systematics of the Bacteria and Archaea.将基因组学纳入细菌和古菌的分类学和系统学中。
Int J Syst Evol Microbiol. 2014 Feb;64(Pt 2):316-324. doi: 10.1099/ijs.0.054171-0.
4
DNA-DNA hybridization values and their relationship to whole-genome sequence similarities.DNA-DNA杂交值及其与全基因组序列相似性的关系。
Int J Syst Evol Microbiol. 2007 Jan;57(Pt 1):81-91. doi: 10.1099/ijs.0.64483-0.
5
Quality criteria were proposed for measurement properties of health status questionnaires.针对健康状况调查问卷的测量属性提出了质量标准。
J Clin Epidemiol. 2007 Jan;60(1):34-42. doi: 10.1016/j.jclinepi.2006.03.012. Epub 2006 Aug 24.
6
Assessing health status and quality-of-life instruments: attributes and review criteria.评估健康状况和生活质量的工具:属性与评审标准
Qual Life Res. 2002 May;11(3):193-205. doi: 10.1023/a:1015291021312.

利益相关者关于健康声称申请的一般科学指南(修订版1)。

General scientific guidance for stakeholders on health claim applications (Revision 1).

出版信息

EFSA J. 2021 Mar 26;19(3):e06553. doi: 10.2903/j.efsa.2021.6553. eCollection 2021 Mar.

DOI:10.2903/j.efsa.2021.6553
PMID:33791037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7996104/
Abstract

[Table: see text] The general guidance for stakeholders on the evaluation of Article 13(1), 13(5) and 14 health claims was first published in March 2011. Since then, the Panel on Dietetic Products Nutrition and Allergies (NDA) has completed the scientific assessment of Article 13(1) claims except for claims put on hold by the European Commission, and has assessedadditional health claim applications submitted pursuant to Articles 13(5), 14 and also 19. In addition, comments received from stakeholders indicate that general issues that are common to all health claims need to be further clarified and addressed. This guidance document aims to explain the general scientific principles applied by the NDA Panel for the scientific assessmentof all health claims and outlines a series of steps for the compilation of applications. The general guidance document represents the views of the NDA Panel based on the experience gained to date with the scientific assessment of health claims, and it may be further updated, as appropriate, when additional issues are addressed.The document also aims to inform applicants of newprovisionsin the pre-submission phase and in the application procedure set out in the General Food Law, as amended by the Transparency Regulation. These new provisions are applicable to all applications submitted as of 27 March 2021. The version of this guidance published in 2016 remains applicable for applications submitted before 27 March 2021.

摘要

[表格:见正文] 利益相关者对第13(1)条、第13(5)条和第14条健康声明评估的一般指南于2011年3月首次发布。自那时以来,营养、新型食品及过敏症专家组(NDA)已完成了对第13(1)条声明的科学评估,但欧洲委员会搁置的声明除外,并已评估了根据第13(5)条、第14条以及第19条提交的其他健康声明申请。此外,从利益相关者收到的评论表明,所有健康声明共有的一般问题需要进一步澄清和解决。本指南文件旨在解释NDA专家组在对所有健康声明进行科学评估时所适用的一般科学原则,并概述编制申请的一系列步骤。该一般指南文件代表了NDA专家组基于迄今在健康声明科学评估中获得的经验所形成的观点,并可能在解决其他问题时酌情进一步更新。本文件还旨在告知申请人《一般食品法》(经《透明度条例》修订)在提交前阶段和申请程序中的新规定。这些新规定适用于2021年3月27日及以后提交的所有申请。2016年发布的本指南版本仍适用于2021年3月27日之前提交的申请。